<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Ning Y</submitter><funding>China Scholarship Council</funding><funding>Austrian Science Fund FWF</funding><funding>Deutsche Forschungsgemeinschaft</funding><pagination>24924-24934</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7618453</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>68(23)</volume><pubmed_abstract>C-Type lectins are a large family of carbohydrate-binding proteins. Langerin is a member of this family and is expressed by Langerhans cells, involved in pathogen recognition and innate immune activation, making it a target for small-molecule modulation in immunology and infectious diseases. We previously identified thiazolopyrimidinones as a series of allosteric inhibitors, but the underlying mechanism remained unclear. In this study, &lt;sup>43&lt;/sup>Ca NMR demonstrated that these fragments induce Ca&lt;sup>2+&lt;/sup> release from the receptor. Our ITC data suggested a competitive relationship between inhibitors and Ca&lt;sup>2+&lt;/sup>, which was further validated by &lt;sup>19&lt;/sup>F NMR spectroscopy showing inhibition of carbohydrate binding. Surprisingly, the fragment binding site was found to be loc</pubmed_abstract><journal>Journal of medicinal chemistry</journal><pubmed_title>Calcium Competitive Inhibition of Langerin by Thiazolopyrimidinones.</pubmed_title><pmcid>PMC7618453</pmcid><funding_grant_id>10.55776/I5771N</funding_grant_id><funding_grant_id>I 5157</funding_grant_id><funding_grant_id>10.55776/I5157</funding_grant_id><funding_grant_id>669831-NA1274/7-1</funding_grant_id><funding_grant_id>I 5771</funding_grant_id><funding_grant_id>202106790019</funding_grant_id><pubmed_authors>Turhan E</pubmed_authors><pubmed_authors>Ruwolt M</pubmed_authors><pubmed_authors>Neu U</pubmed_authors><pubmed_authors>Nazare M</pubmed_authors><pubmed_authors>Kohnke J</pubmed_authors><pubmed_authors>Rademacher C</pubmed_authors><pubmed_authors>Lefebre J</pubmed_authors><pubmed_authors>Efrem NL</pubmed_authors><pubmed_authors>Kurzbach D</pubmed_authors><pubmed_authors>Besch M</pubmed_authors><pubmed_authors>Ning Y</pubmed_authors><pubmed_authors>Amoussa M</pubmed_authors><pubmed_authors>Loll B</pubmed_authors><pubmed_authors>Zheng D</pubmed_authors></additional><is_claimable>false</is_claimable><name>Calcium Competitive Inhibition of Langerin by Thiazolopyrimidinones.</name><description>C-Type lectins are a large family of carbohydrate-binding proteins. Langerin is a member of this family and is expressed by Langerhans cells, involved in pathogen recognition and innate immune activation, making it a target for small-molecule modulation in immunology and infectious diseases. We previously identified thiazolopyrimidinones as a series of allosteric inhibitors, but the underlying mechanism remained unclear. In this study, &lt;sup>43&lt;/sup>Ca NMR demonstrated that these fragments induce Ca&lt;sup>2+&lt;/sup> release from the receptor. Our ITC data suggested a competitive relationship between inhibitors and Ca&lt;sup>2+&lt;/sup>, which was further validated by &lt;sup>19&lt;/sup>F NMR spectroscopy showing inhibition of carbohydrate binding. Surprisingly, the fragment binding site was found to be loc</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Dec</publication><modification>2026-06-10T05:17:48.117Z</modification><creation>2026-06-10T03:07:27.953Z</creation></dates><accession>S-EPMC7618453</accession><cross_references><pubmed>41261040</pubmed><doi>10.1021/acs.jmedchem.5c01756</doi></cross_references></HashMap>